BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology. 2010;51:111-120. [PMID: 19885878 DOI: 10.1002/hep.23271] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 176] [Article Influence: 38.0] [Reference Citation Analysis]
2 Rosato V, Masarone M, Aglitti A, Persico M. The diagnostic conundrum in non-alcoholic fatty liver disease. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00018] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mwinyi J, Boström AE, Pisanu C, Murphy SK, Erhart W, Schafmayer C, Hampe J, Moylan C, Schiöth HB. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2017;1862:314-23. [DOI: 10.1016/j.bbalip.2016.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Xin YN, Geng N, Lin ZH, Cui YZ, Duan HP, Zhang M, Xuan SY. Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One 2014;9:e108132. [PMID: 25250770 DOI: 10.1371/journal.pone.0108132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010;8:70. [PMID: 21192835 DOI: 10.1186/1477-5956-8-70] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
6 Baumann U, Puls F. Steatosis hepatis: Für den Kinderarzt von Bedeutung? Monatsschr Kinderheilkd 2010;158:1070-6. [DOI: 10.1007/s00112-010-2233-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Valle A, Catalán V, Rodríguez A, Rotellar F, Valentí V, Silva C, Salvador J, Frühbeck G, Gómez-ambrosi J, Roca P, Oliver J. Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. Liver Int 2012;32:951-61. [DOI: 10.1111/j.1478-3231.2012.02765.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
8 Kim TH, Jeong CW, Jun HY, Lee C, Noh S, Kim JE, Kim S, Yoon KH. Accuracy of proton magnetic resonance for diagnosing non-alcoholic steatohepatitis: a meta-analysis. Sci Rep 2019;9:15002. [PMID: 31628409 DOI: 10.1038/s41598-019-51302-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Ægidius HM, Veidal SS, Feigh M, Hallenborg P, Puglia M, Pers TH, Vrang N, Jelsing J, Kornum BR, Blagoev B, Rigbolt KTG. Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Sci Rep 2020;10:1148. [PMID: 31980690 DOI: 10.1038/s41598-020-58059-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
10 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.9] [Reference Citation Analysis]
11 Wernberg CW, Ravnskjaer K, Lauridsen MM, Thiele M. The Role of Diagnostic Biomarkers, Omics Strategies, and Single-Cell Sequencing for Nonalcoholic Fatty Liver Disease in Severely Obese Patients. J Clin Med 2021;10:930. [PMID: 33804302 DOI: 10.3390/jcm10050930] [Reference Citation Analysis]
12 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Wang S, Sheng F, Zou L, Xiao J, Li P. Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism. J Adv Res 2021;34:109-22. [PMID: 35024184 DOI: 10.1016/j.jare.2021.06.001] [Reference Citation Analysis]
14 Sanchez C, Poggi M, Morange PE, Defoort C, Martin JC, Tanguy S, Dutour A, Grino M, Alessi MC. Diet modulates endogenous thrombin generation, a biological estimate of thrombosis risk, independently of the metabolic status. Arterioscler Thromb Vasc Biol 2012;32:2394-404. [PMID: 22859493 DOI: 10.1161/ATVBAHA.112.250332] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
15 Chan GG, Koch CM, Connors LH. Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm). J Proteome Res 2017;16:4104-12. [PMID: 28922609 DOI: 10.1021/acs.jproteome.7b00479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Trovato GM, Martines GF, Trovato FM, Pirri C, Pace P, Garozzo A, Castro A, Catalano D. Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci. 2012;57:535-544. [PMID: 21953137 DOI: 10.1007/s10620-011-1903-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
17 Perakakis N, Stefanakis K, Mantzoros CS. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 2020;111S:154320. [PMID: 32712221 DOI: 10.1016/j.metabol.2020.154320] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
18 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
19 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
20 Hannivoort RA, Hernandez-Gea V, Friedman SL. Genomics and proteomics in liver fibrosis and cirrhosis. Fibrogenesis Tissue Repair 2012;5:1. [PMID: 22214245 DOI: 10.1186/1755-1536-5-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
21 Huang B, Yao Y, Li Y, Yang H, Liu H, Liu H, Li D, Shu W, Chen M. Proteomics approach to investigate dynamic protein profile involved in high fat diet-induced fatty liver disease in rats. J Toxicol Pathol 2019;32:223-32. [PMID: 31719749 DOI: 10.1293/tox.2018-0045] [Reference Citation Analysis]
22 Bayliss J, Ooi GJ, De Nardo W, Shah YJH, Montgomery MK, McLean C, Kemp W, Roberts SK, Brown WA, Burton PR, Watt MJ. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. Front Endocrinol (Lausanne) 2021;12:642432. [PMID: 33746906 DOI: 10.3389/fendo.2021.642432] [Reference Citation Analysis]
23 Hörber S, Lehmann R, Fritsche L, Machann J, Birkenfeld AL, Häring HU, Stefan N, Heni M, Fritsche A, Peter A. Lifestyle Intervention Improves Prothrombotic Coagulation Profile in Individuals at High Risk for Type 2 Diabetes. J Clin Endocrinol Metab 2021;106:e3198-207. [PMID: 33659996 DOI: 10.1210/clinem/dgab124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kopec AK, Joshi N, Luyendyk JP. Role of hemostatic factors in hepatic injury and disease: animal models de-liver. J Thromb Haemost. 2016;14:1337-1349. [PMID: 27060337 DOI: 10.1111/jth.13327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
25 Nicholls JM, Francis GD. Anatomical pathology is dead? Long live anatomical pathology. Pathology 2011;43:635-41. [DOI: 10.1097/pat.0b013e32834a404f] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
26 Bell LN, Saxena R, Mattar SG, You J, Wang M, Chalasani N. Utility of formalin-fixed, paraffin-embedded liver biopsy specimens for global proteomic analysis in nonalcoholic steatohepatitis. Proteomics Clin Appl 2011;5:397-404. [PMID: 21656912 DOI: 10.1002/prca.201000144] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
27 Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27:1-13. [PMID: 23554788 DOI: 10.7555/jbr.27.20120077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
28 Lockman KA, Htun V, Sinha R, Treskes P, Nelson LJ, Martin SF, Rogers SM, Le Bihan T, Hayes PC, Plevris JN. Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro. Lipids Health Dis 2016;15:114. [PMID: 27368608 DOI: 10.1186/s12944-016-0283-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
29 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
30 Hassan R, Tammam SN, Safy SE, Abdel-halim M, Asimakopoulou A, Weiskirchen R, Mansour S. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis. European Journal of Pharmaceutics and Biopharmaceutics 2019;134:96-106. [DOI: 10.1016/j.ejpb.2018.11.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
31 Hijona E, Hijona L, Larzabal M, Sarasqueta C, Aldazabal P, Arenas J, Bujanda L. Biochemical determination of lipid content in hepatic steatosis by the Soxtec method. World J Gastroenterol 2010; 16(12): 1495-1499 [PMID: 20333790 DOI: 10.3748/wjg.v16.i12.1495] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
32 Yang B, Zhang J, Sun L, Huang T, Kong Y, Li L, Sun Z, Yin M, Li X. Mapping Novel Biomarkers of Liver Injury by Tissue Proteomic Analysis. ACS Omega 2021;6:7127-38. [PMID: 33748626 DOI: 10.1021/acsomega.1c00152] [Reference Citation Analysis]
33 Zhu Y, Zhang S, Yang C, Xue W, Zhang J, Li J, Zhao J, Xu J, Huang W. [Quantitative analysis of differential proteins in liver tissues of patients with non-alcoholic steatohepatitis using iTRAQ technology]. Nan Fang Yi Ke Da Xue Xue Bao 2021;41:1381-7. [PMID: 34658353 DOI: 10.12122/j.issn.1673-4254.2021.09.13] [Reference Citation Analysis]
34 Hawkins MT, Lewis JH. Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol. 2012;8:1521-1530. [PMID: 22998122 DOI: 10.1517/17425255.2012.724060] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
35 Wattacheril J, Rose KL, Hill S, Lanciault C, Murray CR, Washington K, Williams B, English W, Spann M, Clements R, Abumrad N, Flynn CR. Non-alcoholic fatty liver disease phosphoproteomics: A functional piece of the precision puzzle. Hepatol Res 2017;47:1469-83. [PMID: 28258704 DOI: 10.1111/hepr.12885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
36 Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301:G825-34. [PMID: 21836057 DOI: 10.1152/ajpgi.00145.2011] [Cited by in Crossref: 260] [Cited by in F6Publishing: 225] [Article Influence: 23.6] [Reference Citation Analysis]
37 Huang L, Shao D, Wang Y, Cui X, Li Y, Chen Q, Cui J. Human body-fluid proteome: quantitative profiling and computational prediction. Brief Bioinform 2021;22:315-33. [PMID: 32020158 DOI: 10.1093/bib/bbz160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00043-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Ovchinsky N, Moreira RK, Lefkowitch JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol 2012;19:250-62. [PMID: 22692288 DOI: 10.1097/PAP.0b013e31825c6a20] [Cited by in Crossref: 70] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
40 Fernando H, Wiktorowicz JE, Soman KV, Kaphalia BS, Khan MF, Shakeel Ansari GA. Liver proteomics in progressive alcoholic steatosis. Toxicol Appl Pharmacol 2013;266:470-80. [PMID: 23200777 DOI: 10.1016/j.taap.2012.11.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
41 Nuño-Lámbarri N, Barbero-Becerra VJ, Uribe M, Chávez-Tapia NC. Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach. Int J Mol Sci 2016;17:281. [PMID: 26999105 DOI: 10.3390/ijms17030281] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
42 Aithal GP, Guha N, Fallowfield J, Castera L, Jackson AP. Biomarkers in liver disease: emerging methods and potential applications. Int J Hepatol 2012;2012:437508. [PMID: 23209913 DOI: 10.1155/2012/437508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
43 Cao W, Zhou Y, Li Y, Zhang X, He M, Zang N, Zhou Y, Liao M. iTRAQ-based proteomic analysis of combination therapy with taurine, epigallocatechin gallate, and genistein on carbon tetrachloride-induced liver fibrosis in rats. Toxicol Lett 2015;232:233-45. [PMID: 25448286 DOI: 10.1016/j.toxlet.2014.11.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
44 Yilmaz Y. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease. Clin Chim Acta. 2012;413:1190-1193. [PMID: 22546610 DOI: 10.1016/j.cca.2012.04.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
45 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. [DOI: 10.1017/s0029665110000030] [Cited by in Crossref: 141] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
46 Kampf C, Mardinoglu A, Fagerberg L, Hallström BM, Edlund K, Lundberg E, Pontén F, Nielsen J, Uhlen M. The human liver-specific proteome defined by transcriptomics and antibody-based profiling. FASEB J 2014;28:2901-14. [PMID: 24648543 DOI: 10.1096/fj.14-250555] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
47 Terán Lantarón A, Crespo García J. [Non-alcoholic fatty liver disease. How and who to screen]. Gastroenterol Hepatol 2011;34:278-88. [PMID: 21429628 DOI: 10.1016/j.gastrohep.2010.11.010] [Reference Citation Analysis]
48 Bell LN, Lee L, Saxena R, Bemis KG, Wang M, Theodorakis JL, Vuppalanchi R, Alloosh M, Sturek M, Chalasani N. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol 2010;298:G746-54. [PMID: 20167877 DOI: 10.1152/ajpgi.00485.2009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
49 Li L, Bebek G, Previs SF, Smith JD, Sadygov RG, McCullough AJ, Willard B, Kasumov T. Proteome Dynamics Reveals Pro-Inflammatory Remodeling of Plasma Proteome in a Mouse Model of NAFLD. J Proteome Res 2016;15:3388-404. [PMID: 27439437 DOI: 10.1021/acs.jproteome.6b00601] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
50 Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012;56:1363-1370. [PMID: 22314419 DOI: 10.1016/j.jhep.2011.12.025] [Cited by in Crossref: 141] [Cited by in F6Publishing: 121] [Article Influence: 14.1] [Reference Citation Analysis]
51 Hou W, Janech MG, Sobolesky PM, Bland AM, Samsuddin S, Alazawi W, Syn WK. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease. Biosci Rep 2020;40:BSR20190395. [PMID: 31860081 DOI: 10.1042/BSR20190395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
52 Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010:837419. [PMID: 20300479 DOI: 10.1155/2010/837419] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
53 Lee K, Haddad A, Osme A, Kim C, Borzou A, Ilchenko S, Allende D, Dasarathy S, McCullough A, Sadygov RG, Kasumov T. Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits. Mol Cell Proteomics. 2018;17:2371-2386. [PMID: 30171159 DOI: 10.1074/mcp.ra118.000961] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 6.8] [Reference Citation Analysis]
54 Sun J, Slavov S, Schnackenberg LK, Ando Y, Greenhaw J, Yang X, Salminen W, Mendrick DL, Beger R. Identification of a metabolic biomarker panel in rats for prediction of acute and idiosyncratic hepatotoxicity. Comput Struct Biotechnol J 2014;10:78-89. [PMID: 25379137 DOI: 10.1016/j.csbj.2014.08.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
55 Bhopale KK, Amer SM, Kaphalia L, Soman KV, Wiktorowicz JE, Shakeel Ansari GA, Kaphalia BS. Proteomic Profiling of Liver and Plasma in Chronic Ethanol Feeding Model of Hepatic Alcohol Dehydrogenase-Deficient Deer Mice. Alcohol Clin Exp Res. 2017;41:1675-1685. [PMID: 28792616 DOI: 10.1111/acer.13470] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
56 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
57 Sugimoto K, Takei Y. Clinicopathological features of non-alcoholic fatty liver disease. Hepatol Res. 2011;41:911-920. [PMID: 21951869 DOI: 10.1111/j.1872-034x.2011.00867.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 2.1] [Reference Citation Analysis]
58 Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, Wang M, Rochon J, Chalasani N. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2012;35:600-612. [PMID: 22403816 DOI: 10.1111/j.1365-2036.2011.04982.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
59 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Liu F, Seto WK, Wong DK, Huang FY, Cheung KS, Mak LY, Sharma R, Zhang S, Fung J, Lai CL, Yuen MF. Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. J Infect Dis 2019;220:940-50. [PMID: 31056649 DOI: 10.1093/infdis/jiz223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D, Koek G. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:837-61. [DOI: 10.1016/j.cgh.2017.08.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
62 Morange P, Alessi M. Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thromb Haemost 2017;110:669-80. [DOI: 10.1160/th13-01-0075] [Cited by in Crossref: 65] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
63 Borlak J, Chatterji B, Londhe KB, Watkins PB. Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. Genome Med 2013;5:86. [PMID: 24070255 DOI: 10.1186/gm493] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
64 Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
65 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
66 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
67 Trovato FM, Catalano D, Garozzo A, Martines GF, Pirri C, Trovato GM. ADV36 adipogenic adenovirus in human liver disease. World J Gastroenterol 2014; 20(40): 14706-14716 [PMID: 25356033 DOI: 10.3748/wjg.v20.i40.14706] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
68 Vajro P, Lenta S, Socha P, Dhawan A, Mckiernan P, Baumann U, Durmaz O, Lacaille F, Mclin V, Nobili V. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee. Journal of Pediatric Gastroenterology & Nutrition 2012;54:700-13. [DOI: 10.1097/mpg.0b013e318252a13f] [Cited by in Crossref: 273] [Cited by in F6Publishing: 119] [Article Influence: 27.3] [Reference Citation Analysis]
69 Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M. Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. Mol Syst Biol 2019;15:e8793. [PMID: 30824564 DOI: 10.15252/msb.20188793] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
70 Zhang Y, Fonslow BR, Shan B, Baek MC, Yates JR 3rd. Protein analysis by shotgun/bottom-up proteomics. Chem Rev 2013;113:2343-94. [PMID: 23438204 DOI: 10.1021/cr3003533] [Cited by in Crossref: 778] [Cited by in F6Publishing: 681] [Article Influence: 86.4] [Reference Citation Analysis]
71 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
72 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Reference Citation Analysis]
73 Ray S, Reddy PJ, Jain R, Gollapalli K, Moiyadi A, Srivastava S. Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011;11:2139-61. [PMID: 21548090 DOI: 10.1002/pmic.201000460] [Cited by in Crossref: 155] [Cited by in F6Publishing: 143] [Article Influence: 14.1] [Reference Citation Analysis]
74 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Geller SA. Liver: tissue handling and evaluation. Methods Mol Biol 2014;1180:303-21. [PMID: 25015156 DOI: 10.1007/978-1-4939-1050-2_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Karlsson C, Wallenius K, Walentinsson A, Greasley PJ, Miliotis T, Hammar M, Iaconelli A, Tapani S, Raffaelli M, Mingrone G, Carlsson B. Identification of Proteins Associated with the Early Restoration of Insulin Sensitivity After Biliopancreatic Diversion. J Clin Endocrinol Metab 2020;105:dgaa558. [PMID: 32830851 DOI: 10.1210/clinem/dgaa558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Xu L, Wei Y, Dong D, Yin L, Qi Y, Han X, Xu Y, Zhao Y, Liu K, Peng J. iTRAQ-based proteomics for studying the effects of dioscin against nonalcoholic fatty liver disease in rats. RSC Adv 2014;4:30704. [DOI: 10.1039/c4ra03948c] [Cited by in Crossref: 32] [Article Influence: 4.0] [Reference Citation Analysis]
78 Lim JW, Dillon J, Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World J Gastroenterol 2014; 20(26): 8325-8340 [PMID: 25024592 DOI: 10.3748/wjg.v20.i26.8325] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
79 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
80 Amacher DE. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology 2011;279:10-8. [PMID: 20974209 DOI: 10.1016/j.tox.2010.10.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
81 Rao PK, Merath K, Drigalenko E, Jadhav AYL, Komorowski RA, Goldblatt MI, Rohatgi A, Sarzynski MA, Gawrieh S, Olivier M. Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease. Clin Proteomics 2018;15:10. [PMID: 29527140 DOI: 10.1186/s12014-018-9186-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
82 Martín-Pozuelo G, González-Barrio R, Barberá GG, Albalat A, García-Alonso J, Mullen W, Mischak H, Periago MJ. Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis. Int J Mol Sci 2016;17:E1789. [PMID: 27792191 DOI: 10.3390/ijms17111789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
83 de Wit NJ, Afman LA, Mensink M, Müller M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J Hepatol. 2012;57:1370-1373. [PMID: 22796155 DOI: 10.1016/j.jhep.2012.07.003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 9.8] [Reference Citation Analysis]
84 Page S, Birerdinc A, Estep M, Stepanova M, Afendy A, Petricoin E, Younossi Z, Chandhoke V, Baranova A. Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example. PLoS One 2013;8:e56009. [PMID: 23405244 DOI: 10.1371/journal.pone.0056009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
85 Baker ES, Burnum-Johnson KE, Jacobs JM, Diamond DL, Brown RN, Ibrahim YM, Orton DJ, Piehowski PD, Purdy DE, Moore RJ, Danielson WF 3rd, Monroe ME, Crowell KL, Slysz GW, Gritsenko MA, Sandoval JD, Lamarche BL, Matzke MM, Webb-Robertson BJ, Simons BC, McMahon BJ, Bhattacharya R, Perkins JD, Carithers RL Jr, Strom S, Self SG, Katze MG, Anderson GA, Smith RD. Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics 2014;13:1119-27. [PMID: 24403597 DOI: 10.1074/mcp.M113.034595] [Cited by in Crossref: 43] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
86 Yang M, Xu D, Liu Y, Guo X, Li W, Guo C, Zhang H, Gao Y, Mao Y, Zhao J. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0131664. [PMID: 26121037 DOI: 10.1371/journal.pone.0131664] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
87 Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells 2020;9:E1005. [PMID: 32316690 DOI: 10.3390/cells9041005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]